Sharon Larkin Net Worth

The estimated Net Worth of Sharon Larkin is at least $134 Thousand dollars as of 7 September 2023. Sharon Larkin owns over 30,889 units of Senseonics Inc stock worth over $115,206 and over the last 3 years Sharon sold SENS stock worth over $18,842.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sharon Larkin SENS stock SEC Form 4 insiders trading

Sharon has made over 1 trades of the Senseonics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Sharon sold 30,889 units of SENS stock worth $18,842 on 7 September 2023.

The largest trade Sharon's ever made was selling 30,889 units of Senseonics Inc stock on 7 September 2023 worth over $18,842. On average, Sharon trades about 5,148 units every 0 days since 2021. As of 7 September 2023 Sharon still owns at least 292,476 units of Senseonics Inc stock.

You can see the complete history of Sharon Larkin stock trades at the bottom of the page.

What's Sharon Larkin's mailing address?

Sharon's mailing address filed with the SEC is C/O SENSEONICS HOLDINGS, INC., 20451 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876.

Insiders trading at Senseonics Inc

Over the last 9 years, insiders at Senseonics Inc have traded over $36,720,504 worth of Senseonics Inc stock and bought 30,963,337 units worth $56,759,340 . The most active insiders traders include Peter J Barris, M James Barrett, and Douglas A Roeder. On average, Senseonics Inc executives and independent directors trade stock every 45 days with the average trade being worth of $313,683. The most recent stock trade was executed by Sharon Larkin on 7 September 2023, trading 30,889 units of SENS stock currently worth $18,842.

What does Senseonics Inc do?

senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm"​) system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Complete history of Sharon Larkin stock trades at Senseonics Inc

Senseonics Inc executives and stock owners

Senseonics Inc executives and other stock owners filed with the SEC include:

• Timothy Goodnow,
  President, Chief Executive Officer, Director
• Francine Kaufman,
  Chief Medical Officer, Director
• Mukul Jain,
  Chief Operating Officer
• Dr. Timothy T. Goodnow,
  Pres, CEO & Director
• Dr. Francine Ratner Kaufman M.D.,
  Chief Medical Officer & Director
• Dr. Mukul Jain,
  Chief Operating Officer
• Mirasol Panlilio,
  Vice President and General Manager - Global Commercial Operations
• Stephen DeFalco,
  Independent Chairman of the Board
• Douglas Prince,
  Independent Director
• Douglas Roeder,
  Independent Director
• Peter Klein,
  Independent Director
• Edward Fiorentino,
  Independent Director
• Steven Edelman,
  Independent Director
• Robert Schumm,
  Director
• Anthony Raab,
  Director
• Nick Tressler,
  Chief Financial Officer, Treasurer, Secretary
• Kenneth L. Horton,
  Gen. Counsel & Corp. Devel. Advisor
• Nick B. Tressler M.B.A.,
  CFO, Sec. & Treasurer
• Sharon Larkin,
  
• Jon D Isaacson,
  Chief Financial Officer
• Michael J. Gill,
  Vice President of U.S. Sales
• M James Barrett,
  Director
• Lynne E Kelley,
  Chief Medical Officer
• Peter J Barris,
  10% owner
• R Don Elsey,
  CFO, Secretary and Treasurer
• Enterprise Associates 9 L P...,
  
• Enterprise Associates 10 L ...,
  
• Management Partners Viii, L...,
  
• Holdings Corp Phc,
  
• John Marotta,
  Director
• Kenneth L Horton,
  GC & Corp. Development Advisor
• Frederick T. Sullivan,
  Chief Financial Officer